Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Sorrento Therapeutics, Inc.
Study ID
NCT05472649
Status
Enrolling By Invitation

Conditions

  • Long-term Follow-up

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gene-Modified Cell Therapy — BIOLOGICAL
    No investigational cell product will be administered

Study Details

Observational long-term follow-up study of patients who have been exposed to a gene-modified cell therapy produced by ex vivo transduction of immune cells expressing viral or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc.

Key Dates

Start date
Jun 16, 2021
Status verified
Jan 2023
Primary completion
Dec 31, 2036
Completion
May 31, 2037

Study Design

Enrollment
1 participants (estimated)

Arms

  • Arm: Participants exposed to Gene-Modified Cell Therapy

Primary Outcome Measure

Long-term safety of previous treatment with gene-modified cells [ Time Frame: Baseline through end of study (approximately 15 years) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center Clinical Research Unit, University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By research site
Abramson Cancer Center Clinical Research Unit, University of Pennsylvania· Philadelphia, PA